Anxiety and mood disorders are more prevalent among patients after COVID-19 critical illness vs after severe pneumonia unrelated to COVID-19.
The FDA has granted Fast Track designation to rezpegaldesleukin for the treatment of moderate to severe atopic dermatitis.
The pooled prevalence of chronic painful neuropathy is 41.22% among individuals with chemotherapy-induced peripheral neuropathy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback